Cargando…

Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas

Osteosarcoma (OS) is the most common bone malignancy without a reliable therapeutic target. Glypican‐3 (GPC3) mutation and upregulation have been detected in multidrug resistant OS, and anti‐GPC3 immunotherapy can effectively suppress the growth of organoids. Further profiling of GPC3 mutations and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nie, Jun‐Hua, Yang, Tao, Li, Hong, Li, Sheng, Li, Ting‐Ting, Ye, Hai‐Shan, Lu, Meng‐Di, Chu, Xiao, Zhong, Guo‐Qing, Zhou, Jie‐Long, Wu, Mo‐Li, Zhang, Yu, Liu, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530858/ https://www.ncbi.nlm.nih.gov/pubmed/35946078 http://dx.doi.org/10.1111/cas.15521

Ejemplares similares

Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target
por: Nie, Jun-Hua, et al.
Publicado: (2021)

Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality
por: Yu, Lei, et al.
Publicado: (2022)

Identification of Abnormal Spindle Microtubule Assembly as a Promising Therapeutic Target for Osteosarcoma
por: Lin, Peng, et al.
Publicado: (2020)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
por: Zheng, Xiufeng, et al.
Publicado: (2022)

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations
por: Lu, Meng-Di, et al.
Publicado: (2022)

MicroRNAs: a novel promising therapeutic target for cerebral ischemia/reperfusion injury?
por: Min, Xiao-li, et al.
Publicado: (2015)

Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma (Review)
por: Liao, Yu-Xin, et al.
Publicado: (2019)

Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
por: Wang, Zenan, et al.
Publicado: (2019)

Ferroptosis in osteosarcoma: A promising future
por: Liu, Xiang, et al.
Publicado: (2022)

Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe
por: Han, Hai-Hao, et al.
Publicado: (2018)

Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis
por: Ren, Hai-Yong, et al.
Publicado: (2016)

Assessment of GSK1904529A as a promising anti-osteosarcoma agent
por: Fei, Hao-Dong, et al.
Publicado: (2017)

mTOR: An attractive therapeutic target for osteosarcoma?
por: Ding, Liu, et al.
Publicado: (2016)

Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma
por: Li, Yuanyuan, et al.
Publicado: (2019)

Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature
por: Yang, Sheng-Li, et al.
Publicado: (2014)

ADCK1 is a potential therapeutic target of osteosarcoma
por: Zhuo, Bao-biao, et al.
Publicado: (2022)

Identification of Gαi3 as a promising target for osteosarcoma treatment
por: Bian, Zheng-jun, et al.
Publicado: (2022)

Glypican-5 is a tumor suppressor in non-small cell lung cancer cells
por: Guo, Lixia, et al.
Publicado: (2016)

Dysplastic Nodules with Glypican-3 Positive Immunostaining: A Risk for Early Hepatocellular Carcinoma
por: Gong, Li, et al.
Publicado: (2014)

Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis
por: Xiao, Wei-Kai, et al.
Publicado: (2014)

Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
por: Zhang, T, et al.
Publicado: (2017)

Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling
por: Li, Fuchuan, et al.
Publicado: (2011)

Elevated intraspinal pressure in traumatic spinal cord injury is a promising therapeutic target
por: Yang, Chao-Hua, et al.
Publicado: (2022)

Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector
por: Liu, Quan, et al.
Publicado: (2017)

Evaluation for clinical and prognostic implications of glypican-3 and α-fetoprotein in hepatocellular carcinoma: a new subtype?
por: Ye, Lin, et al.
Publicado: (2020)

Overexpression of Annexin A2 promotes proliferation by forming a Glypican 1/c-Myc positive feedback loop: prognostic significance in human glioma
por: Li, Xin, et al.
Publicado: (2021)

Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma
por: Li, Kesang, et al.
Publicado: (2015)

Frequent reduction or loss of DCC gene expression in human osteosarcoma.
por: Horstmann, M. A., et al.
Publicado: (1997)

Therapeutic application of extracellular vesicles in kidney disease: promises and challenges
por: Lv, Lin‐Li, et al.
Publicado: (2017)

Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
por: Park, Jeong A, et al.
Publicado: (2023)

Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis
por: Zhang, Jian, et al.
Publicado: (2018)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas
por: El-Saadany, Sherif, et al.
Publicado: (2018)

Glypican 3 as a Serum Marker for Hepatoblastoma
por: Zhou, Shengmei, et al.
Publicado: (2017)

Glypican 3-Targeted Therapy in Hepatocellular Carcinoma
por: Nishida, Takahiro, et al.
Publicado: (2019)

Glypicans and cytonemes unite to distribute Wnt ligands
por: Waghmare, Indrayani, et al.
Publicado: (2021)

Correction: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
por: Zhang, T., et al.
Publicado: (2019)

Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells
por: Yao, Gebing, et al.
Publicado: (2019)

Neuroendocrine Tumors Show Altered Expression of Chondroitin Sulfate, Glypican 1, Glypican 5, and Syndecan 2 Depending on Their Differentiation Grade
por: García-Suárez, Olivia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bici4mlubrc7f4f70sn7j6oh8k